PortalPublikationenImpact of preoperative risk on metastatic progression and ca...

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy

Standard

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. / Boehm, Katharina; Leyh-Bannurah, Sami-Ramzi; Rosenbaum, Clemens; Brandi, Laurenz S; Budäus, Lars; Graefen, Markus; Huland, Hartwig; Haferkamp, Axel; Tilki, Derya.

in: BJU INT, Jahrgang 120, Nr. 5, 11.2017, S. 666-672.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Boehm, K, Leyh-Bannurah, S-R, Rosenbaum, C, Brandi, LS, Budäus, L, Graefen, M, Huland, H, Haferkamp, A & Tilki, D 2017, 'Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy', BJU INT, Jg. 120, Nr. 5, S. 666-672. https://doi.org/10.1111/bju.13887

APA

Boehm, K., Leyh-Bannurah, S-R., Rosenbaum, C., Brandi, L. S., Budäus, L., Graefen, M., Huland, H., Haferkamp, A., & Tilki, D. (2017). Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. BJU INT, 120(5), 666-672. https://doi.org/10.1111/bju.13887

Vancouver

Boehm K, Leyh-Bannurah S-R, Rosenbaum C, Brandi LS, Budäus L, Graefen M et al. Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. BJU INT. 2017 Nov;120(5):666-672. https://doi.org/10.1111/bju.13887

Bibtex

@article{9fa41caa46984ad697301ed4e3088545,
title = "Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy",
abstract = "OBJECTIVE: To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP).PATIENTS AND METHODS: The records of 6 943 patients who underwent RP at a European tertiary centre were analysed. Biochemical recurrence (BCR), metastatic disease and CSM were assessed for patients with adverse pathology at RP, and stratified according to preoperative low- vs intermediate-/high-risk PCa groups. Kaplan-Meier, cumulative incidence, Cox regression and competing risk regression analyses were performed.RESULTS: In patients with extracapsular extension, the metastatic disease rate was 1.6% vs 8% (P < 0.001) and the CSM rate was 2% vs 5% (P = 0.041) for low vs intermediate-/high-risk patients, respectively, at 10 years. In patients with pathological Gleason score ≥3+4, the metastatic disease rate was 3.0% vs 12% (P < 0.001) and the CSM rate was 3% vs 8%, respectively (P < 0.001). In patients with positive surgical margins (PSMs), the metastatic disease rate was 2.9% vs 15% (P < 0.001) and the CSM rate was 4% vs 10%, respectively (P = 0.0001). Low-risk status was a predictive factor for metastatic disease in patients with pathological Gleason score ≥3+4 (hazard ratio [HR] 0.51), pathological Gleason score ≥4+3 (HR 0.41) and PSMs (HR 0.46) and was a predictive factor for CSM risk in patients with pathological Gleason score ≥3+4 (HR 0.62).CONCLUSIONS: Patients with low-risk PCa were at significantly lower risk of metastatic disease and CSM than their intermediate-/high-risk counterparts, when adverse pathological features were identified at RP. This should be emphasized in the decision-making process after RP.",
keywords = "Aged, Cohort Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Risk Factors, Journal Article",
author = "Katharina Boehm and Sami-Ramzi Leyh-Bannurah and Clemens Rosenbaum and Brandi, {Laurenz S} and Lars Bud{\"a}us and Markus Graefen and Hartwig Huland and Axel Haferkamp and Derya Tilki",
note = "{\textcopyright} 2017 The Authors BJU International {\textcopyright} 2017 BJU International Published by John Wiley & Sons Ltd.",
year = "2017",
month = nov,
doi = "10.1111/bju.13887",
language = "English",
volume = "120",
pages = "666--672",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy

AU - Boehm, Katharina

AU - Leyh-Bannurah, Sami-Ramzi

AU - Rosenbaum, Clemens

AU - Brandi, Laurenz S

AU - Budäus, Lars

AU - Graefen, Markus

AU - Huland, Hartwig

AU - Haferkamp, Axel

AU - Tilki, Derya

N1 - © 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

PY - 2017/11

Y1 - 2017/11

N2 - OBJECTIVE: To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP).PATIENTS AND METHODS: The records of 6 943 patients who underwent RP at a European tertiary centre were analysed. Biochemical recurrence (BCR), metastatic disease and CSM were assessed for patients with adverse pathology at RP, and stratified according to preoperative low- vs intermediate-/high-risk PCa groups. Kaplan-Meier, cumulative incidence, Cox regression and competing risk regression analyses were performed.RESULTS: In patients with extracapsular extension, the metastatic disease rate was 1.6% vs 8% (P < 0.001) and the CSM rate was 2% vs 5% (P = 0.041) for low vs intermediate-/high-risk patients, respectively, at 10 years. In patients with pathological Gleason score ≥3+4, the metastatic disease rate was 3.0% vs 12% (P < 0.001) and the CSM rate was 3% vs 8%, respectively (P < 0.001). In patients with positive surgical margins (PSMs), the metastatic disease rate was 2.9% vs 15% (P < 0.001) and the CSM rate was 4% vs 10%, respectively (P = 0.0001). Low-risk status was a predictive factor for metastatic disease in patients with pathological Gleason score ≥3+4 (hazard ratio [HR] 0.51), pathological Gleason score ≥4+3 (HR 0.41) and PSMs (HR 0.46) and was a predictive factor for CSM risk in patients with pathological Gleason score ≥3+4 (HR 0.62).CONCLUSIONS: Patients with low-risk PCa were at significantly lower risk of metastatic disease and CSM than their intermediate-/high-risk counterparts, when adverse pathological features were identified at RP. This should be emphasized in the decision-making process after RP.

AB - OBJECTIVE: To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP).PATIENTS AND METHODS: The records of 6 943 patients who underwent RP at a European tertiary centre were analysed. Biochemical recurrence (BCR), metastatic disease and CSM were assessed for patients with adverse pathology at RP, and stratified according to preoperative low- vs intermediate-/high-risk PCa groups. Kaplan-Meier, cumulative incidence, Cox regression and competing risk regression analyses were performed.RESULTS: In patients with extracapsular extension, the metastatic disease rate was 1.6% vs 8% (P < 0.001) and the CSM rate was 2% vs 5% (P = 0.041) for low vs intermediate-/high-risk patients, respectively, at 10 years. In patients with pathological Gleason score ≥3+4, the metastatic disease rate was 3.0% vs 12% (P < 0.001) and the CSM rate was 3% vs 8%, respectively (P < 0.001). In patients with positive surgical margins (PSMs), the metastatic disease rate was 2.9% vs 15% (P < 0.001) and the CSM rate was 4% vs 10%, respectively (P = 0.0001). Low-risk status was a predictive factor for metastatic disease in patients with pathological Gleason score ≥3+4 (hazard ratio [HR] 0.51), pathological Gleason score ≥4+3 (HR 0.41) and PSMs (HR 0.46) and was a predictive factor for CSM risk in patients with pathological Gleason score ≥3+4 (HR 0.62).CONCLUSIONS: Patients with low-risk PCa were at significantly lower risk of metastatic disease and CSM than their intermediate-/high-risk counterparts, when adverse pathological features were identified at RP. This should be emphasized in the decision-making process after RP.

KW - Aged

KW - Cohort Studies

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Risk Factors

KW - Journal Article

U2 - 10.1111/bju.13887

DO - 10.1111/bju.13887

M3 - SCORING: Journal article

C2 - 28437038

VL - 120

SP - 666

EP - 672

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 5

ER -